Compare

Novonesis A/S/€NSISB

1D1W1M3M6MYTD1Y5YMAX

About Novonesis A/S

Novonesis A/S is a biotechnology company formed in January 2024 through the merger of Novozymes and Chr. Hansen. Headquartered in Lyngby, Denmark, the company specializes in developing biosolutions, including enzymes, functional proteins, and microorganisms, serving over 30 industries such as food and beverage, agriculture, and pharmaceuticals. With a global presence encompassing more than 23 manufacturing sites and nearly 40 R&D and application centers, Novonesis employs approximately 10,000 individuals worldwide. The company is committed to sustainability, aiming for carbon neutrality by 2050 and a 75% reduction in scope 1 and 2 emissions by 2030. Novonesis leverages its extensive expertise to create innovative biosolutions that address global challenges in health, nutrition, and environmental sustainability.
Ticker
€NSISB
Sector
Materials
Primary listing
XGAT
Employees
11,098
Headquarters
Lyngby, Denmark
Website
www.novonesis.com

Novonesis A/S Metrics

BasicAdvanced
€29B
45.56
€1.35
0.62
€0.88
1.43%

What the Analysts think about Novonesis A/S

Analyst ratings (Buy, Hold, Sell) for Novonesis A/S stock.
Analyst projections of the future price of Novonesis A/S stock.

Bulls say / Bears say

Organic sales grew 8% in the first half, with growth across both divisions and developed and emerging markets. Novonesis raised its 2026 growth forecast to 7–8%, suggesting demand is holding up better than management had expected. (Novonesis)
The adjusted EBITDA margin rose to 37.7% and adjusted net profit increased 8% in the first half. Free cash flow before acquisitions was 14% of sales and net debt fell to 1.8 times EBITDA, giving the company room to fund investment while maintaining financial flexibility. (Novonesis)
A planned €1 billion share buyback through 2029 offers a direct return to shareholders, alongside investment in growth. The announcement followed strong results and an upgraded outlook, and helped lift the shares after the results release. (Novonesis, The Wall Street Journal)
Growth is uneven in some end markets: Human Health grew only 4% in the second quarter, with North American supplements still soft, while Plant was hurt by weak US farm economics. That could limit momentum outside the stronger food and household-care businesses. (Investing.com, Novonesis)
Elevated investment could constrain near-term cash returns: 2026 capital expenditure is forecast at 12–14% of sales, and first-half free cash flow before acquisitions was flat year on year. The payoff from capacity expansion and the new ERP system therefore needs to justify a substantial cash commitment. (Novonesis)
Novonesis faces a longer-term competitive and policy risk: its chief executive warned that slow European approvals could let Chinese biosolutions competitors catch up. Delays could make it harder for the company to commercialise new products quickly in a market where regulatory speed matters. (Bloomberg)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.

Novonesis A/S Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Novonesis A/S Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing Novonesis A/S

AllEURUSDGBP
Funds
Fund name
Fund size
€NSISB weighting
Vanguard ESG Developed Europe All Cap£V3EA
€125M0.21%
Vanguard ESG Developed Europe All Cap£V3EL
€35M0.21%
Vanguard FTSE Developed Europe ex UK$VERE
€1.4B0.20%
Vanguard FTSE Developed Europe ex UK€VERX
€3.3B0.20%
Vanguard FTSE Developed Europe ex UK£VERX
€3.3B0.20%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.